Agilent Technologies Inc
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrome… Read more
Agilent Technologies Inc - Asset Resilience Ratio
Agilent Technologies Inc (A) has an Asset Resilience Ratio of 12.22% as of April 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Agilent Technologies Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Agilent Technologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.49 Billion | 12.22% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.49 Billion | 12.22% |
Asset Resilience Insights
- Moderate Liquidity: Agilent Technologies Inc has 12.22% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Agilent Technologies Inc Industry Peers by Asset Resilience Ratio
Compare Agilent Technologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Agilent Technologies Inc (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Agilent Technologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-10-31 | 11.22% | $1.33 Billion | $11.85 Billion | -3.55pp |
| 2023-10-31 | 14.77% | $1.59 Billion | $10.76 Billion | +4.77pp |
| 2022-10-31 | 10.00% | $1.05 Billion | $10.53 Billion | -4.71pp |
| 2021-10-31 | 14.71% | $1.57 Billion | $10.71 Billion | -1.90pp |
| 2020-10-31 | 16.61% | $1.60 Billion | $9.63 Billion | +1.99pp |
| 2019-10-31 | 14.62% | $1.38 Billion | $9.45 Billion | -11.69pp |
| 2018-10-31 | 26.31% | $2.25 Billion | $8.54 Billion | -5.47pp |
| 2017-10-31 | 31.78% | $2.68 Billion | $8.43 Billion | +2.50pp |
| 2016-10-31 | 29.28% | $2.29 Billion | $7.82 Billion | +26.05pp |
| 2015-10-31 | 3.24% | $242.00 Million | $7.48 Billion | -- |
| 2014-10-31 | 0.00% | $0.00 | $10.76 Billion | -- |
| 2013-10-31 | 0.00% | $0.00 | $10.69 Billion | -- |
| 2012-10-31 | 0.10% | $11.00 Million | $10.54 Billion | -- |
| 2011-10-31 | 0.00% | $0.00 | $9.06 Billion | -- |
| 2010-10-31 | 15.99% | $1.55 Billion | $9.70 Billion | +15.80pp |
| 2009-10-31 | 0.18% | $14.00 Million | $7.61 Billion | -0.14pp |
| 2008-10-31 | 0.32% | $24.00 Million | $7.44 Billion | -0.05pp |
| 2005-10-31 | 0.37% | $25.00 Million | $6.75 Billion | +0.36pp |
| 2002-10-31 | 0.01% | $1.00 Million | $8.20 Billion | -2.96pp |
| 2001-10-31 | 2.97% | $237.00 Million | $7.99 Billion | -- |